Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives $11.40 Average Price Target from Analysts

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) has been given a consensus rating of “Buy” by the seven research firms that are currently covering the stock, MarketBeat reports. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $11.40.

RVPH has been the subject of several analyst reports. HC Wainwright lowered their target price on shares of Reviva Pharmaceuticals from $14.00 to $11.00 and set a “buy” rating for the company in a report on Wednesday, January 22nd. Maxim Group raised shares of Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price objective for the company in a research note on Friday, January 10th. Roth Capital raised Reviva Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 10th. D. Boral Capital reissued a “buy” rating and set a $15.00 price target on shares of Reviva Pharmaceuticals in a research note on Tuesday, January 21st. Finally, Roth Mkm began coverage on Reviva Pharmaceuticals in a research report on Friday, January 10th. They issued a “buy” rating and a $7.00 price objective on the stock.

Institutional Trading of Reviva Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the stock. Raymond James Financial Inc. purchased a new stake in shares of Reviva Pharmaceuticals during the fourth quarter worth $25,000. Cornerstone Select Advisors LLC purchased a new stake in Reviva Pharmaceuticals during the 4th quarter worth about $32,000. Drive Wealth Management LLC acquired a new stake in Reviva Pharmaceuticals in the 4th quarter valued at about $36,000. Tower Research Capital LLC TRC boosted its stake in shares of Reviva Pharmaceuticals by 848.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 26,775 shares of the company’s stock valued at $48,000 after buying an additional 23,953 shares during the period. Finally, XTX Topco Ltd acquired a new position in shares of Reviva Pharmaceuticals during the fourth quarter worth about $45,000. Institutional investors and hedge funds own 63.18% of the company’s stock.

Reviva Pharmaceuticals Price Performance

RVPH stock opened at $1.18 on Friday. The company has a market capitalization of $39.46 million, a price-to-earnings ratio of -1.06 and a beta of -0.09. Reviva Pharmaceuticals has a 1-year low of $0.60 and a 1-year high of $4.28. The business has a 50 day simple moving average of $1.77 and a two-hundred day simple moving average of $1.47.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.